Remove Biopharma Remove Doctors Remove Physicians Remove Prescription
article thumbnail

Veradigm® Digital Health Media Works to Message the Right Physicians at the Right Time

PM360

As pharma reps’ access to physicians continues to decline, this case study examines the effectiveness of reaching physicians through other means—the EHR. Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. THE CHALLENGE.

article thumbnail

Five ways COVID-19 has changed healthcare provision and what it means for pharmas

Clarivate

2021 surveys of patients and physicians in the United States conducted by Clarivate show that: Much of care delivery has gone virtual. Three in five physicians in the United States (60%) report having conducted virtual consultations, as do 35% of patients. physicians; Source: Clarivate, Taking the Pulse(R) U.S.

Pharma 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

RxPass offers more than 50 select prescriptions at no additional cost for $5 per month. In classic Amazon style, its pharmacy offers two-day shipping on prescriptions by mail, with same-day delivery available in seven markets, with plans to add a dozen more cities by year end.

Retail 52
article thumbnail

Accelerating HCP engagement in Singapore using customer reference data

Veeva

Quickly confirm specialty data, prescriptive authority, and sample eligibility to ensure compliance with regulations and privacy laws. Veeva OpenData provides additional insight into registrars and new doctors. This enables field reps to target the right physicians and opportunities in real time. Streamline compliance.

Sales 52
article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. Which physicians see these patients? sales, medical science liaisons, etc.).